Skip to main content
Premium Trial:

Request an Annual Quote

Paul Billings, Robert Friel, Gregory Summe, Richard Wender, Kerry Frey, Eric Henderson

Paul Billings has been appointed chairman of Signature Genomic Laboratories’ board of directors, the firm said this week.
Billings previously was senior vice president for corporate development and senior geneticist at Laboratory Corporation of America. He has also been executive vice president and chief scientific and medical officer at GeneSage.
Billings received his MD and his PhD in immunology from Harvard University in 1979 and completed his clinical training in internal medicine and medical genetics at the University of Washington in Seattle in 1983.

PerkinElmer last week said that company President and Chief Operating Officer Robert Friel will replace current CEO Gregory Summe on Feb. 1. In accordance with the company’s planned strategy for succession of responsibility, Summe will continue to hold his post as executive chairman of the board through April 2009.
Friel, who started at PerkinElmer in 1999 as chief financial officer and was promoted to president and COO in 2007, will retain his post as president.

Epigenomics has named Richard Wender to the company’s medical advisory board for colorectal cancer screening.
Wender is alumni professor and chair of the Department of Family and Community Medicine at Thomas Jefferson University in Philadelphia.

BioForce Nanosciences has shuffled its management, making President and Chief Operating Officer Kerry Frey the new CEO, while retaining the title of president, and moving current CEO Eric Henderson into the post of executive vice president and chief scientific officer, a newly created position.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.